Literature DB >> 25344576

Admission glycaemia and its association with acute coronary syndrome in Emergency Department patients with chest pain.

Logan S Gardner1, Sallyanne Nguyen-Pham1, Jaimi H Greenslade2, William Parsonage1, Michael D'Emden1, Martin Than3, Sally Aldous3, Anthony Brown1, Louise Cullen2.   

Abstract

BACKGROUND: This study aims to evaluate admission blood glucose level (BGL) in patients presenting to the emergency department (ED) as a risk factor for a major adverse cardiac event (MACE) on presentation and up to 30 days post discharge. Admission BGL is a prognostic indicator in patients with confirmed acute coronary syndrome (ACS). It is unclear if admission BGL improves the diagnosis and stratification of patients presenting to the ED with suspected ACS.
METHODS: This study is an analysis of data collected from a prospective observational study. The study population consisted of ED patients from Brisbane, Australia and Christchurch, New Zealand. Patients were enrolled between November 2007 and February 2011. Admission BGL was taken as part of routine admission blood with fasting status unknown. The primary end point for this study was a MACE at presentation and up to 30 days post discharge. Logistic regression analyses examined the relationship between admission hyperglycaemia and MACE. A hyperglycaemic threshold of 7 mmol/L was chosen based on WHO standards.
RESULTS: A total of 1708 patients were eligible. A MACE was identified in 336 patients (19.7%) within 30 days. Of these 98 had confirmed unstable angina and 232 had non-ST elevation myocardial infarction. Hyperglycaemia was identified in 476 (27.9%) patients with 147 (30.9%) having a MACE. Admission BGL >7 mmol/L was demonstrated as an independent predictor of a MACE (OR1.51 CI 1.06 to 2.14). Gender, age, hypertension, dyslipidaemia, family history, ischaemic ECG and positive troponin remained important factors.
CONCLUSIONS: Admission BGL is an independent risk factor for a MACE in patients with suspected ACS. Hyperglycaemia should be considered a risk factor for MACEs and consideration be given to its inclusion in existing diagnostic tools. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  acute coronary syndrome

Mesh:

Substances:

Year:  2014        PMID: 25344576     DOI: 10.1136/emermed-2014-204046

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  5 in total

1.  Newly Diagnosed Diabetes and Stress Glycaemia and Its' Association with Acute Coronary Syndrome.

Authors:  Gordana Kamceva; Marija Vavlukis; Darko Kitanoski; Sashko Kedev
Journal:  Open Access Maced J Med Sci       Date:  2015-09-30

2.  Association of Admission Glycaemia With High Grade Atrioventricular Block in ST-Segment Elevation Myocardial Infarction Undergoing Reperfusion Therapy: An Observational Study.

Authors:  Bi Huang; Xinjie Wang; Yanmin Yang; Jun Zhu; Yan Liang; Huiqiong Tan; Litian Yu; Xin Gao; Han Zhang; Juan Wang
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

3.  Association of Admission Blood Glucose Level with Major Adverse Cardiac Events in Acute Coronary Syndrome; a Cohort Study.

Authors:  Mostafa Alavi-Moghaddam; Mohamad Parsa-Mahjoob; Robabeh Ghodssi-Ghassemabadi; Bita Bitazar
Journal:  Arch Acad Emerg Med       Date:  2019-04-16

4.  Selective protein kinase C inhibition switches time-dependent glucose cardiotoxicity to cardioprotection.

Authors:  Sean Brennan; Simona Esposito; Muhammad I M Abdelaziz; Christopher A Martin; Samir Makwana; Mark W Sims; Iain B Squire; Parveen Sharma; Amy E Chadwick; Richard D Rainbow
Journal:  Front Cardiovasc Med       Date:  2022-09-07

5.  Hyperglycemia is a predictor of prognosis in traumatic brain injury: Tertiary intensive care unit study.

Authors:  Berna Terzioglu; Osman Ekinci; Zafer Berkman
Journal:  J Res Med Sci       Date:  2015-12       Impact factor: 1.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.